Priapism: Diagnosis and Management

Anatomy and Physiology

• The penis contains three erectile bodies: two corpora cavernosa and the corpus spongiosum, with normal erection involving arterial inflow and venous outflow regulation through smooth muscle relaxation and contraction in the corpora cavernosa 1, 2, 3
• The corpora cavernosa are paired cylindrical structures responsible for penile rigidity during erection 2
• The corpus spongiosum surrounds the urethra and forms the glans penis, which typically remains flaccid during priapism episodes 2, 3

Pathophysiology

• Priapism results from failure of the normal detumescence mechanism, leading to prolonged erection unrelated to sexual stimulation 1, 4
• Ischemic priapism is characterized by venous outflow obstruction, causing blood stagnation in the corpora cavernosa with hypoxia, hypercarbia, and acidosis 5, 6
• Non-ischemic priapism is caused by unregulated arterial inflow, typically from traumatic arterio-cavernosal fistula formation, resulting in persistent but non-ischemic erection 2, 3

Diagnosis

• All patients presenting with prolonged erection must be evaluated emergently to differentiate between ischemic and non-ischemic subtypes 5, 6
• Essential history elements include duration of erection, degree of pain, history of trauma, medication use, and previous priapism episodes 1, 2, 3
• Cavernosal blood gas analysis is the gold standard for differentiating priapism types, with ischemic priapism showing pO2 <30 mmHg, pCO2 >60 mmHg, and pH <7.25 5, 6

Treatment and Management

• Immediate urologic emergency treatment with corporal aspiration and intracavernosal phenylephrine injection is required for ischemic priapism 6
• Intracavernosal phenylephrine injection combined with aspiration has a 43-81% success rate 5, 6
• Surgical shunting is indicated when repeated intracavernosal phenylephrine injections fail, with distal shunts having 60-80% success rates 5, 6
• Non-ischemic priapism does not require urgent urologic intervention, and many cases resolve spontaneously 7
• Selective arterial embolization is the treatment of choice for non-ischemic priapism, with high success rates 7

Special Population: Sickle Cell Disease

• Patients with sickle cell disease presenting with ischemic priapism should receive immediate urologic intracavernosal treatment, with concurrent systemic sickle cell interventions 5, 6
• Systemic sickle cell treatments alone resolved priapism in only 0-37% of patients, and urologic intervention should not be delayed 5

Critical Timing and Outcomes

• The risk of permanent erectile dysfunction increases significantly after 24 hours of ischemia and approaches 90% after 48 hours, emphasizing the need for prompt treatment 5, 6
• Early intervention with intracavernosal phenylephrine and aspiration can reduce the risk of erectile dysfunction 5
• Delayed treatment results in cavernosal smooth muscle necrosis, fibrosis, and permanent erectile dysfunction 1, 4

Pathophysiology of Priapism

Ischemic and Non-Ischemic Priapism

• The American Urological Association notes that intracavernosal vasodilators, such as papaverine, cause prolonged smooth muscle relaxation that prevents normal venous compression, leading to priapism 8
• The use of phosphodiesterase-5 inhibitors can disrupt the balance between vasorelaxing and vasoconstrictive factors, contributing to priapism, although the exact mechanism is not fully understood, and non-ischemic priapism is characterized by unregulated arterial inflow into corpora cavernosa, typically from traumatic arterio-cavernosal fistula formation 8
• Perineal or penile trauma can cause laceration of the cavernous artery, creating an abnormal communication between the artery and erectile tissue, leading to non-ischemic priapism 9
• The distinction between ischemic and non-ischemic priapism is critical, as sympathomimetics are ineffective in non-ischemic priapism due to patent venous outflow, and may cause systemic cardiovascular effects 9

Clinical Presentation and Diagnosis

• Non-ischemic priapism is characterized by a penis that is neither fully rigid nor painful due to maintained venous drainage, and represents a hemodynamic abnormality rather than true ischemia 8
• Stuttering priapism represents a recurrent variant of ischemic priapism with the same veno-occlusive pathophysiology, and is characterized by repetitive, self-limited episodes with intervening periods of complete detumescence 8

Management of Pediatric Priapism

Diagnostic Evaluation

• Urgent differentiation between ischemic and non‑ischemic priapism is mandatory and is achieved by corporal blood‑gas analysis – ischemic priapism shows pO₂ < 30 mmHg, pCO₂ > 60 mmHg, pH < 7.25; non‑ischemic priapism shows normal arterial values【10】.
• A duration of erection longer than 4 hours markedly increases the risk of corporal tissue damage【10】.
• Painful, fully rigid corpora cavernosa indicate ischemic priapism, whereas a painless, partially tumescent erection suggests non‑ischemic priapism【10】.
• Recent perineal, genital, or pelvic trauma points toward non‑ischemic priapism caused by an arterio‑cavernosal fistula【10】.
• Medication or drug exposure history should be obtained because certain agents can precipitate priapism【10】.
• Family or personal history of sickle‑cell disease or hematologic malignancy is relevant; priapism occurs in 2.5–3.3 % of boys diagnosed with chronic myeloid leukemia【11】.
• Physical examination findings:
  
  • Rigid, tender corpora cavernosa → ischemic; partially tumescent → non‑ischemic【10】.
  • Glans penis and corpus spongiosum remain soft in priapism【10】.
  • Presence of splenomegaly may signal an underlying hematologic malignancy such as CML【11】.
• Laboratory work‑up:
  
  • Complete blood count with differential and hemoglobin electrophoresis to screen for sickle‑cell disease or leukemia【11】.
  • Penile duplex Doppler ultrasound is useful when blood‑gas results are equivocal; ischemic priapism shows minimal or absent cavernous arterial flow【10】.

Immediate Management of Ischemic Priapism (Time‑Critical)

• Do not postpone urologic intervention while awaiting hematologic results; immediate treatment is required【11】.
• First‑line therapy: intracavernosal phenylephrine (100–500 µg) with or without corporal aspiration【10】.
• Adjunctive measure: corporal aspiration and saline irrigation to evacuate hypoxic blood and restore normal metabolism【11】.
• Timing thresholds: irreversible corporal tissue damage begins after 24 hours of ischemia, and the risk of permanent erectile dysfunction rises sharply after 48 hours【11】.

Management of Non‑Ischemic Priapism (Less Urgent)

• Urgent urologic intervention is not required; many cases resolve spontaneously with observation【12】.
• If intervention becomes necessary, selective arterial embolization is the preferred treatment (guideline recommendation, not tied to a specific citation).

Hematologic Disease‑Specific Considerations

• Concurrent urologic and hematologic management is essential, but urologic therapy must never be delayed【11】.
• Chronic Myeloid Leukemia (CML)‑associated priapism: immediate cytoreduction using hydroxyurea, leukapheresis, or exchange transfusion should be performed alongside penile aspiration and phenylephrine injection【11】.
• Sickle‑cell disease‑associated priapism: aggressive hydration, analgesia, and exchange transfusion to lower HbS to < 30 % should accompany standard ischemic priapism treatment【13】【14】.

Critical Pitfalls to Avoid

• Avoid delaying urologist consultation; early involvement improves outcomes【11】.
• Phenylephrine is the only recommended sympathomimetic; epinephrine or norepinephrine should not be used because of cardiovascular safety concerns (guideline principle, not citation‑linked).
• Do not assume priapism in children is benign; it frequently signals serious underlying pathology such as leukemia【11】.